Avelumab + Avelumab + Avelumab + Avelumab + Avelumab + Avelumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hodgkins Lymphoma
Conditions
Hodgkins Lymphoma
Trial Timeline
Mar 10, 2016 → Apr 11, 2019
NCT ID
NCT02603419About Avelumab + Avelumab + Avelumab + Avelumab + Avelumab + Avelumab
Avelumab + Avelumab + Avelumab + Avelumab + Avelumab + Avelumab is a phase 1 stage product being developed by Pfizer for Hodgkins Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02603419. Target conditions include Hodgkins Lymphoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02603419 | Phase 1 | Terminated |
Competing Products
18 competing products in Hodgkins Lymphoma